Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) are now a first-line maintenance treatment in ovarian cancer and have been approved in other cancer types, including breast, pancreatic and prostate. Despite their efficacy, and as is the case for other targeted therapies, resistance to PARPi has been reported clinically and is generating a growing patient population of unmet clinical need. Here, we discuss...

Topics

Join the communities discussing this publication.

• Integrated Circuits and Semiconductor Failure Analysis
• Ovarian cancer diagnosis and treatment
• PARP inhibition in cancer therapy